Mode of Action BIBF 1120* slide kit

Boehringer Ingelheim

BIBF 1120 is an investigational small molecule simultaneously inhibiting 3 of the RTKs demonstrated to aid in the regulation of angiogenesis: FGFR, PDGFR, and VEGFR.

In preclinical studies, BIBF 1120 has been shown to be a membrane-permeable inhibitor that binds to the ATP binding site of FGFR, PDGFR, and VEGFR, blocking receptor activation and subsequent downstream signaling cascades. This type of inhibition may be a viable strategy to inhibit tumor angiogenesis, tumor growth, and the potential for metastasis.1

References:

1. Hilberg F, Roth GJ, Krssak M, et al. Cancer Res. 2008;68(12):4774-4782.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on